Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer

Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search

1996 • 834 citations

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer

1996 • 538 citations

Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine

1995 • 506 citations

Vaccinia Virus: A Tool for Research and Vaccine Development

1991 • 410 citations

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

1996 • 398 citations

Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report

1995 • 296 citations

LONG-TERM RESULTS OF RADIATION THERAPY FOR PROSTATE CANCER RECURRENCE FOLLOWING RADICAL PROSTATECTOMY

1998 • 214 citations

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study

1996 • 147 citations

Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine

1997 • 144 citations

Phase I clinical trials.

1977 • 127 citations

A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate

1995 • 109 citations

Abnormalities of Cell-Mediated Immunocompetence in Genitourinary Cancer

1974 • 67 citations

Immune Responses Elicited by Recombinant Vaccinia-Human Immunodeficiency Virus (HIV) Envelope and HIV Envelope Protein: Analysis of the Durability of Responses and Effect of Repeated Boosting

1994 • 46 citations

REPLY BY AUTHORS

1998 • 28 citations

Phase I clinical trial: T‐cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA‐A0201‐specific peptides from prostate‐specific membrane antigen

1996 • 25 citations

Adjuvant immunotherapy (BCG) in Stage D prostate cancer

1982 • 23 citations

Specificity of cell membrane antigens in prostatic cancer.

1975 • 22 citations